These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 17868260)

  • 1. Peripheral circulating activated b-cell populations are associated with nephritis and disease activity in patients with systemic lupus erythematosus.
    Dolff S; Wilde B; Patschan S; Dürig J; Specker C; Philipp T; Kribben A; Witzke O
    Scand J Immunol; 2007 Nov; 66(5):584-90. PubMed ID: 17868260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus.
    Patschan S; Dolff S; Kribben A; Dürig J; Patschan D; Wilde B; Specker C; Philipp T; Witzke O
    Clin Exp Immunol; 2006 Aug; 145(2):235-42. PubMed ID: 16879242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?
    Bijl M; van Lopik T; Limburg PC; Spronk PE; Jaegers SM; Aarden LA; Smeenk RJ; Kallenberg GG
    J Autoimmun; 1998 Oct; 11(5):457-63. PubMed ID: 9802929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus.
    Wong CK; Lit LC; Tam LS; Li EK; Lam CW
    Rheumatology (Oxford); 2005 Aug; 44(8):989-94. PubMed ID: 15870153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.
    Jacobi AM; Odendahl M; Reiter K; Bruns A; Burmester GR; Radbruch A; Valet G; Lipsky PE; Dörner T
    Arthritis Rheum; 2003 May; 48(5):1332-42. PubMed ID: 12746906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated production of serum B-cell-attracting chemokine-1 (BCA-1/CXCL13) is correlated with childhood-onset lupus disease activity, severity, and renal involvement.
    Ezzat M; El-Gammasy T; Shaheen K; Shokr E
    Lupus; 2011 Jul; 20(8):845-54. PubMed ID: 21576203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of cellular FLICE-inhibitory protein in peripheral blood B lymphocytes in patients with systemic lupus erythematosus is associated with clinical characteristics.
    Tao J; Dong J; Li Y; Liu YQ; Yang J; Wu Y; Li L; Shen GX; Tan ZJ; Tu YT
    J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):433-7. PubMed ID: 19335730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE).
    Schiffer L; Kümpers P; Davalos-Misslitz AM; Haubitz M; Haller H; Anders HJ; Witte T; Schiffer M
    Nephrol Dial Transplant; 2009 Dec; 24(12):3708-12. PubMed ID: 19602475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of CCR2 and CXCR3 in the T cell-mediated response occurring during lupus flares.
    Amoura Z; Combadiere C; Faure S; Parizot C; Miyara M; Raphaël D; Ghillani P; Debre P; Piette JC; Gorochov G
    Arthritis Rheum; 2003 Dec; 48(12):3487-96. PubMed ID: 14673999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process.
    Papadimitraki ED; Choulaki C; Koutala E; Bertsias G; Tsatsanis C; Gergianaki I; Raptopoulou A; Kritikos HD; Mamalaki C; Sidiropoulos P; Boumpas DT
    Arthritis Rheum; 2006 Nov; 54(11):3601-11. PubMed ID: 17075805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adrenomedullin--a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus.
    Mak A; Cheung BM; Mok CC; Leung R; Lau CS
    Rheumatology (Oxford); 2006 Oct; 45(10):1266-72. PubMed ID: 16595522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new CD21low B cell population in the peripheral blood of patients with SLE.
    Wehr C; Eibel H; Masilamani M; Illges H; Schlesier M; Peter HH; Warnatz K
    Clin Immunol; 2004 Nov; 113(2):161-71. PubMed ID: 15451473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The circulating lymphocyte profiles in patients with discoid lupus erythematosus and systemic lupus erythematosus suggest a pathogenetic relationship.
    Wouters CH; Diegenant C; Ceuppens JL; Degreef H; Stevens EA
    Br J Dermatol; 2004 Apr; 150(4):693-700. PubMed ID: 15099365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis.
    Lee HT; Shiao YM; Wu TH; Chen WS; Hsu YH; Tsai SF; Tsai CY
    J Rheumatol; 2010 Jan; 37(1):45-52. PubMed ID: 19955043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus.
    Lajaunias F; Ida A; Kikuchi S; Fossati-Jimack L; Martinez-Soria E; Moll T; Law CL; Izui S
    Arthritis Rheum; 2003 Jun; 48(6):1612-21. PubMed ID: 12794829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B cells lacking RP105, a novel B cell antigen, in systemic lupus erythematosus.
    Koarada S; Tada Y; Ushiyama O; Morito F; Suzuki N; Ohta A; Miyake K; Kimoto M; Nagasawa K
    Arthritis Rheum; 1999 Dec; 42(12):2593-600. PubMed ID: 10616005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
    Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
    Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.
    Szekanecz E; Szucs G; Szekanecz Z; Tarr T; Antal-Szalmás P; Szamosi S; Szántó J; Kiss E
    J Autoimmun; 2008 Dec; 31(4):372-6. PubMed ID: 18926664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study.
    Dhir V; Singh AP; Aggarwal A; Naik S; Misra R
    Lupus; 2009 Aug; 18(9):785-91. PubMed ID: 19578102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.